SAB Biotherapeutics Inc Dossier - Source-backed chat

SAB Biotherapeutics Inc

SABSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.69

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.06Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $278.4M

Enterprise Value $264.1M

Shares Outstanding 91M diluted

Moat Rating None

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

SAB Biotherapeutics (SABS) is a clinical-stage biopharmaceutical company uniquely positioned to disrupt the Type 1 Diabetes (T1D) therapeutic landscape with its lead asset, SAB-142. SAB-142 is a fully human anti-thymocyte immunoglobulin (hATG) designed to delay the onset and progression of Stage 3 T1D. Unlike traditional rabbit-derived ATG, SAB-142 offers a superior safety profile with low immunogenicity and no serum sickness, enabling safe, chronic redosing. Backed by a robust cash position of $217.6 million following a $95 million public offering in March 2026, the company has an operational runway extending through 2028. This fully funds the registrational Phase 2b SAFEGUARD trial, which is on track to complete enrollment by the end of 2026, with topline data expected in the second half of 2027. De-risked by FDA confirmation that C-peptide AUC can serve as a surrogate endpoint for accelerated approval, SABS represents a high-upside opportunity in a multi-billion dollar market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$11.18

High · most bullish analyst$16.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The SAFEGUARD trial experiences enrollment delays extending into 2027, pushing back the topline data readout. Clinical results fail to show statistically significant C-peptide preservation compared to placebo, or unexpected safety signals emerge during chronic redosing. The lack of clinical efficacy or regulatory setbacks forces the company to halt the program, leaving it dependent on its early-stage pipeline and severely depressing the stock price.

Base CaseCentral scenario

The Phase 2b SAFEGUARD trial successfully completes enrollment by the end of 2026. Topline data in 2H 2027 demonstrates significant C-peptide preservation and improved glycemic control, matching or exceeding the efficacy of rabbit ATG but with a vastly superior safety profile (no serum sickness or anti-drug antibodies). The company leverages the FDA's accelerated approval pathway using C-peptide AUC as a surrogate endpoint, leading to a BLA filing in 2028. Commercial manufacturing is successfully scaled up via the strategic agreement with Emergent BioSolutions.

Bull CaseUpside scenario

The bull case for SAB-142 is built on three pillars: first, the mechanism of action is clinically de-risked as anti-thymocyte globulin (ATG) has demonstrated statistically significant C-peptide preservation in three independent trials; second, SAB-142 is a fully human polyclonal antibody that avoids the serum sickness and high immunogenicity associated with animal-derived alternatives, enabling safe chronic redosing; third, the company possesses a highly durable competitive moat because replicating its transchromosomic bovine herd technology from scratch requires years of capital-intensive effort.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Lead Asset: SAB-142 is a fully human immunotherapy that avoids the immunogenicity and serum sickness limitations of animal-derived ATGs, allowing for chronic redosing.
De-risked Regulatory Pathway: FDA written correspondence confirmed that C-peptide AUC can serve as a surrogate endpoint for accelerated approval, significantly shortening the timeline to market.
Strong Financial Runway: With $217.6 million in cash and investments as of Q1 2026, the company is fully funded through 2028, covering all SAFEGUARD trial costs and pre-commercial activities.
Proprietary Platform: The Tc Bovine platform produces fully human, multi-specific polyclonal antibodies at scale without human donors, creating high barriers to entry and pipeline optionality.

Key Investment Risks

Clinical Development Risk: SABS is a clinical-stage company whose valuation is heavily tied to the success of a single asset (SAB-142) in an ongoing Phase 2b trial.
Execution and Enrollment Timelines: Any delays in completing the SAFEGUARD trial enrollment by the end of 2026 will push back the anticipated 2H 2027 data readout and increase cash burn.
Platform Validation: Following the historical failure of its COVID-19 candidate (SAB-185), the platform's commercial viability remains unproven until SAB-142 achieves regulatory approval.

Thesis Invalidation Triggers

Failure of the Phase 2b SAFEGUARD trial to meet its primary endpoint of C-peptide preservation.
Emergence of severe adverse events, such as systemic immunosuppression or serum sickness, during the SAFEGUARD trial.
Inability to complete patient enrollment for the SAFEGUARD trial by mid-2027, indicating severe operational delays.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.